Long-Term Outcomes of Teplizumab in Routine Clinical Care

NCT07360080

Status	RECRUITING
Sponsor	Sanofi
Enrollment	1,000 participants

Key Eligibility Criteria

Inclusion (4)

- Participants who have received at least 1 teplizumab infusion within 6 weeks prior to enrollment.
- Participants must have a confirmed diagnosis of Stage 2 T1D according to the treating physician at the time of the first infusion of teplizumab.
- (Note: Participants who progress to Stage 3 T1D by Week 6 will still be eligible, provided they were in Stage 2 at the time of the first teplizumab infusion.)
- • Participants (or their legal guardians, as applicable) who provide appropriate written or electronic informed consent/assent as applicable for the age of the participant and as per local regulations.

Exclusion (4)

- Participants who had participated in a previous clinical trial for teplizumab.
- Participants enrolled in a clinical trial within 6 months prior to study enrollment.
- (Note: Participants enrolled in other observational studies may be included.)
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1 total)

Investigational Site Number: 3760001, Ramat Gan, Israel